TBX 2400
Alternative Names: TBX-2400Latest Information Update: 30 Nov 2021
At a glance
- Originator Taiga Biotechnologies
- Class Antineoplastics; Cell therapies; Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Acute myeloid leukaemia; Myelofibrosis
Most Recent Events
- 10 Nov 2021 Phase-I clinical trials in Acute myeloid leukaemia (Second-line therapy or greater) in Italy, Croatia (IV) (NCT04709458)
- 10 Nov 2021 Phase-I clinical trials in Myelofibrosis (Second-line therapy or greater) in Croatia (IV) (NCT04709458)
- 10 Nov 2021 Phase-I clinical trials in Myelofibrosis (Second-line therapy or greater) in Italy, Croatia (IV) (NCT04709458)